Significant Options Trading on Wednesday: UTHR, URGN, DSGN

Written by Emily J. Thompson, Senior Investment Analyst

DSGN+4.34%

UTHR+0.09%

URGN-2.95%

Source: NASDAQ.COM

Updated: Dec 17 2025

0mins

Source: NASDAQ.COM

UroGen Pharma Options Activity: UroGen Pharma Ltd (URGN) has seen a significant options volume of 20,539 contracts today, equating to about 2.1 million underlying shares, which is 192% of its average daily trading volume over the past month.
High Volume Call Option for URGN: The $24 strike call option expiring on February 20, 2026, has particularly high activity with 10,010 contracts traded, representing approximately 1.0 million underlying shares.
Design Therapeutics Options Activity: Design Therapeutics Inc (DSGN) has recorded an options volume of 5,000 contracts today, representing around 500,000 underlying shares, which is 164.8% of its average daily trading volume over the past month.
High Volume Call Option for DSGN: The $9 strike call option expiring on January 16, 2026, has seen all 5,000 contracts traded today, corresponding to approximately 500,000 underlying shares.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like DSGN with instant alerts to capture every critical market movement.

Sign up for free to build your custom watchlist and receive professional-grade stock notifications.

DSGN

$10.57+Infinity%1D

Analyst Views on DSGN

Wall Street analysts forecast DSGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DSGN is 15.00 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Analyst Rating

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 10.130

Low

13.00

Averages

15.00

High

18.00

Current: 10.130

Low

13.00

Averages

15.00

High

18.00

Oppenheimer

Outperform

initiated

$18

2026-01-07

Reason

Oppenheimer

Price Target

$18

AI Analysis

2026-01-07

initiated

Outperform

Reason

Oppenheimer initiated coverage of Design Therapeutics with an Outperform rating and $18 price target. The firm notes the company's lead program is Friedreich's ataxia, wherein the drug was optimized following a clinical trial and could be a "game changer," according to an FA well-regarded key opinion leader, while follow-on programs include Myotonic Dystrophy 1 and Fuchs Endothelial Corneal Dystrophy. Oppenheimer sees high probability of success for Design Therapeutics' platform given that early clinical data demonstrates broad distribution across tissues and high/sustained PK exposure. The company's biggest catalyst is the second half of 2026 readout in FA that, in the firm's view, will provide significant derisking of its platform/pipeline, driving 50%-100%-plus potential upside and attracting investor/pharma interest.

Craig-Hallum

Adam Vogel

Buy

initiated

$15

2025-12-03

Reason

Craig-Hallum

Adam Vogel

Price Target

$15

2025-12-03

initiated

Buy

Reason

Craig-Hallum analyst Adam Vogel initiated coverage of Design Therapeutics with a Buy rating and $15 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DSGN

Unlock Now

About DSGN

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.